ANABOLICRX

The education library

Stenox and fluoxymesterone: medical history, evidence and risks

← All education profiles

Educational evidence summary, not personal medical advice. AI-assisted research and editorial preparation by AnabolicRX. Sources checked 23 October 2026. No independent clinical review completed. Current Canadian product authorization is not established by this article.

Identity and terminology

This library uses Stenox as the reference-entry name; the substance discussed is fluoxymesterone, also associated with the historical Halotestin brand. Brand names, a molecule and a particular authorized product are different things. A study of pharmaceutical fluoxymesterone does not authenticate another product carrying its name.

Fluoxymesterone is an oral synthetic androgen with a 17-alpha modification. Historical US labeling describes treatment of specific testosterone-deficiency conditions, established delayed puberty and palliation of selected recurrent breast cancers. Those are medical contexts, not evidence supporting athletic enhancement. The label reviewed is dated 2002, with a 2006 database revision; it is not a statement of current Canadian prescribing practice. Historical Halotestin label

What the medical history actually shows

The strongest account of a drug's history follows the conditions and outcomes studied. For fluoxymesterone, the research reviewed here spans delayed growth and breast cancer. These are distinct evidence streams. A growth study cannot answer whether cancer treatment prolongs survival, and a cancer response cannot establish benefits for healthy people.

Historical use also should not be confused with today's preferred care. This review documents older research rather than offering treatment selection. This article does not establish current endocrine or oncology treatment recommendations, or Canadian product availability.

Breast cancer: disease setting matters

A 1991 updated randomized trial analysis compared tamoxifen alone with tamoxifen plus fluoxymesterone in 238 postmenopausal patients with metastatic breast cancer. Reported response rates were 42% and 54%; that comparison did not meet the conventional statistical threshold. Median time to progression was longer in the combination group, 11.6 versus 6.5 months, with a statistically significant difference. Overall survival and response duration were similar. Ingle and colleagues, 1991

That result supports a narrow conclusion: adding the androgen affected one disease-control outcome in this historical population. It does not establish a survival advantage. The paper also explored subgroups, but exploratory signals require confirmation rather than being treated as separate proof. The earlier report and this updated analysis should not be counted as two independent trials.

A different randomized study, published in 2006, examined adjuvant treatment after surgery for early-stage, estrogen-receptor-positive breast cancer. Among 541 eligible postmenopausal women, adding fluoxymesterone to tamoxifen did not significantly improve relapse-free or overall survival after a median 11.4 years of follow-up. Virilization was more frequent with the combination. Ingle and colleagues, 2006

These findings are not interchangeable. Metastatic disease control and prevention of recurrence after surgery are different questions. Together they show why an educational profile should name the disease stage, comparison and endpoint instead of simply saying a steroid “treats cancer.” Neither trial establishes an appropriate current regimen; this profile intentionally provides none.

Delayed growth: speed of growth is not final height

In a small 1985 study of 17 boys with delayed growth, nine of whom also had delayed puberty, growth velocity increased during treatment and remained above the earlier rate afterward. Height relative to bone age did not change significantly. This was a small treated series, so it cannot by itself establish how much adult height treatment causes. Stanhope and colleagues, 1985

A 1982 study followed 61 boys and included untreated observation periods for comparison. Growth accelerated, but interpretation of final height involved predictions as well as observed outcomes; only a subset had measured adult height. A prediction is an estimate, not the same endpoint as actual adult height. Lenko and colleagues, 1982

A later follow-up examined 82 treated boys, mostly with constitutional delay. Their final heights exceeded initial predictions on average, and an untreated comparison group helped assess prediction accuracy. However, the study was not a randomized comparison proving that the entire difference resulted from treatment. Selection, the underlying growth pattern and prediction error still matter. Strickland and colleagues, 1993

The practical educational distinction is between growing faster for a period and becoming taller as an adult. Those outcomes can diverge. These papers concern evaluated developmental conditions; they do not justify using an androgen to change normal adolescent growth.

Pharmacology beyond the androgen receptor

A laboratory study found that fluoxymesterone inhibited the enzyme 11β-hydroxysteroid dehydrogenase type 2, which participates in cortisol inactivation. The investigators used human cell preparations and intact cells, supported by molecular modeling. This is mechanistic evidence that the molecule can affect another biological pathway. Experimental study, 2012

Cell experiments do not tell us how frequently a patient will develop a blood-pressure complication or quantify an individual's risk. A mechanism can help explain what to investigate without proving a clinical outcome. This distinction is particularly important when online descriptions turn a laboratory finding into a confident promise or a precise risk estimate.

Organ-system risks and interactions

The historical label warns of cholestatic liver injury, peliosis and liver tumors; fluid retention can worsen heart, kidney or liver disease. It also lists increased red-cell concentration, cholesterol changes, reproductive suppression, menstrual disruption, potentially irreversible virilization and mood symptoms. Pregnancy is contraindicated, breastfeeding is discouraged, and childhood use requires specialist assessment because bone maturation may advance. Oral anticoagulant effects can increase, while glucose changes may alter insulin needs. These are reasons for clinician review, not self-adjustment instructions. Historical label

The 2006 cancer trial supplies direct human evidence of increased virilization in its treatment group. Conversely, an older growth paper's report of no observed androgenic adverse effects cannot establish lifetime safety: a study may be too small, too short or focused on other outcomes to detect uncommon harms. Cancer trial Growth follow-up

A numerical risk table would imply more certainty than the reviewed evidence supports. This review therefore distinguishes reported hazards from their unknown frequency in other populations. A fuller safety review remains necessary, including contemporary evidence about cardiovascular, psychiatric and reproductive outcomes specific to this molecule.

Direct reproductive evidence requires careful wording

A historical human investigation reported marked suppression of testosterone during fluoxymesterone exposure. Although lower sperm counts appeared at some time points, consistently significant suppression of spermatogenesis was not demonstrated. The two observations must not be collapsed into either a reliable contraceptive effect or reassurance about fertility. This small historical evidence also cannot establish a dependable individual recovery course. Primary human study

Canadian status: a cancelled record is a specific finding

Health Canada's indexed Drug Product Database record identifies HALOTESTIN, DIN 00030902, as a human fluoxymesterone product with status “Cancelled Post Market.” That establishes the status of this record; it does not explain the cancellation or exhaustively establish the status of every fluoxymesterone product in Canada. The cancellation reason and date were not verified in this review. Health Canada product record

Canada's Controlled Drugs and Substances Act lists anabolic steroids in Schedule IV. Product authorization and controlled-substance classification are separate questions. This profile does not interpret an individual's possession, importation or supply situation, and it does not provide purchasing advice. Official Canadian schedule

Common misconceptions